Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Launched by VANDERBILT UNIVERSITY · Sep 23, 2009
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 18-65 year of age
- • Undergoing elective abdominal or bariatric surgery
- • May have normal or elevated ALT/AST levels
- Exclusion Criteria:
- • Presence of viral hepatitis
- • Significant alcohol use
- • Intercurrent infections
- • Use of any thiazolidinediones
About Vanderbilt University
Vanderbilt University is a prestigious research institution renowned for its commitment to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on collaboration across various disciplines, Vanderbilt leverages its state-of-the-art facilities and a diverse team of experts to conduct rigorous clinical studies. The university is dedicated to improving patient outcomes by exploring novel therapeutic interventions and enhancing understanding of disease mechanisms. Through its robust clinical research infrastructure, Vanderbilt University aims to contribute significantly to the scientific community and the development of effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Nashville, Tennessee, United States
Patients applied
Trial Officials
Charles R Flynn, PhD
Principal Investigator
Vanderbilt University Medical Center
Najji Abumrad, MD
Study Chair
Vanderbilt University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials